Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Altimmune (ALT) over the last 14 years, with Q3 2025 value amounting to $8.7 million.

  • Altimmune's Gains from Investment Securities rose 3537.25% to $8.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 3537.25%. This contributed to the annual value of $6.6 million for FY2024, which is 3146.34% up from last year.
  • Altimmune's Gains from Investment Securities amounted to $8.7 million in Q3 2025, which was up 3537.25% from $8.1 million recorded in Q2 2025.
  • Over the past 5 years, Altimmune's Gains from Investment Securities peaked at $8.7 million during Q3 2025, and registered a low of -$1.8 million during Q1 2022.
  • Moreover, its 5-year median value for Gains from Investment Securities was $2.6 million (2021), whereas its average is $3.0 million.
  • In the last 5 years, Altimmune's Gains from Investment Securities tumbled by 30454.55% in 2022 and then skyrocketed by 124859.94% in 2024.
  • Altimmune's Gains from Investment Securities (Quarter) stood at -$860000.0 in 2021, then soared by 114.53% to $125000.0 in 2022, then tumbled by 70.4% to $37000.0 in 2023, then tumbled by 94.59% to $2000.0 in 2024, then soared by 432967.85% to $8.7 million in 2025.
  • Its Gains from Investment Securities was $8.7 million in Q3 2025, compared to $8.1 million in Q2 2025 and $678000.0 in Q1 2025.